Form 4: Trevi Therapeutics Director David Meeker Granted 45,000 Stock Options

Trevi Therapeutics, Inc. Director David P. Meeker was granted 45,000 nonstatutory stock options with an exercise price of $6.25, as reported in a recent SEC Form 4 filing.

Summary

• David P. Meeker, a Director of Trevi Therapeutics, Inc. (TRVI), was granted 45,000 nonstatutory stock options on June 11, 2025.
• The options have an exercise price of $6.25 per share.
• The derivative security itself was acquired at a price of $0.00, indicating it was a grant.
• These options are scheduled to fully vest on the earlier of (i) the first anniversary of the grant date (June 11, 2026) or (ii) the date of the next annual meeting of stockholders of the Issuer held following the grant date.
• Vesting is contingent upon Mr. Meeker's continued service as a director, employee, or consultant of Trevi Therapeutics.
• The options have an expiration date of June 10, 2035.
• Following this transaction, David P. Meeker directly beneficially owns 45,000 derivative securities (nonstatutory stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This is a routine compensation event that aligns director incentives with shareholder interests, which is generally viewed favorably, but it does not indicate significant operational or financial news.

Positives

• The grant of stock options to Director David P. Meeker aligns his financial interests with those of the shareholders, incentivizing long-term value creation.
• Equity compensation is a standard practice that helps attract and retain experienced board members.

Future Outlook

The vesting schedule for the granted options indicates a future commitment from the director, with full vesting expected by the first anniversary of the grant date or the next annual meeting, subject to continued service.

Industry Context

The grant of stock options to directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to align the interests of board members with those of shareholders and to provide performance incentives.

Corporate Governance

Related Party Transactions

• The grant of 45,000 nonstatutory stock options to David P. Meeker, a Director of Trevi Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: While not directly impacting employees, this type of compensation structure is common across leadership, setting a precedent for equity-based incentives.

Next Steps

• The options will vest according to the specified schedule (earlier of first anniversary of grant or next annual meeting), subject to continued service.
• Upon vesting, the director will have the right to exercise the options at the stated exercise price of $6.25 per share until the expiration date of June 10, 2035.

Key Dates

Recommendation

Keywords

Trevi Therapeutics, TRVI, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Nonstatutory Stock Option